Your browser doesn't support javascript.
loading
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera, Timothy P S; Jovcheva, Eleonora; Mevellec, Laurence; Vialard, Jorge; De Lange, Desiree; Verhulst, Tinne; Paulussen, Caroline; Van De Ven, Kelly; King, Peter; Freyne, Eddy; Rees, David C; Squires, Matthew; Saxty, Gordon; Page, Martin; Murray, Christopher W; Gilissen, Ron; Ward, George; Thompson, Neil T; Newell, David R; Cheng, Na; Xie, Liang; Yang, Jennifer; Platero, Suso J; Karkera, Jayaprakash D; Moy, Christopher; Angibaud, Patrick; Laquerre, Sylvie; Lorenzi, Matthew V.
Afiliação
  • Perera TPS; Janssen Research and Development, Beerse, Belgium.
  • Jovcheva E; Janssen Research and Development, Beerse, Belgium.
  • Mevellec L; Janssen Research and Development, Val de Reuil, France.
  • Vialard J; Janssen Research and Development, Beerse, Belgium.
  • De Lange D; Janssen Research and Development, Beerse, Belgium.
  • Verhulst T; Janssen Research and Development, Beerse, Belgium.
  • Paulussen C; Janssen Research and Development, Beerse, Belgium.
  • Van De Ven K; Janssen Research and Development, Beerse, Belgium.
  • King P; Janssen Research and Development, Beerse, Belgium.
  • Freyne E; Janssen Research and Development, Beerse, Belgium.
  • Rees DC; Astex Pharmaceuticals, Cambridge, United Kingdom.
  • Squires M; Astex Pharmaceuticals, Cambridge, United Kingdom.
  • Saxty G; Astex Pharmaceuticals, Cambridge, United Kingdom.
  • Page M; Janssen Research and Development, Beerse, Belgium.
  • Murray CW; Astex Pharmaceuticals, Cambridge, United Kingdom.
  • Gilissen R; Janssen Research and Development, Beerse, Belgium.
  • Ward G; Astex Pharmaceuticals, Cambridge, United Kingdom.
  • Thompson NT; Astex Pharmaceuticals, Cambridge, United Kingdom.
  • Newell DR; Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Cheng N; Janssen Research and Development, Shanghai, China.
  • Xie L; Janssen Research and Development, Shanghai, China.
  • Yang J; Janssen Research and Development, Shanghai, China.
  • Platero SJ; Janssen Research and Development, Spring House, Pennsylvania.
  • Karkera JD; Janssen Research and Development, Spring House, Pennsylvania.
  • Moy C; Janssen Research and Development, Spring House, Pennsylvania.
  • Angibaud P; Janssen Research and Development, Val de Reuil, France.
  • Laquerre S; Janssen Research and Development, Spring House, Pennsylvania.
  • Lorenzi MV; Janssen Research and Development, Spring House, Pennsylvania. mlorenzi@its.jnj.com.
Mol Cancer Ther ; 16(6): 1010-1020, 2017 06.
Article em En | MEDLINE | ID: mdl-28341788
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Quinoxalinas / Receptores de Fatores de Crescimento de Fibroblastos / Inibidores de Proteínas Quinases / Descoberta de Drogas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Bélgica País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Quinoxalinas / Receptores de Fatores de Crescimento de Fibroblastos / Inibidores de Proteínas Quinases / Descoberta de Drogas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Bélgica País de publicação: Estados Unidos